In contrast to F-MS, both untreated and IFN-β-treated patients showed little difference in the frequency of CD56+ cells within total T cells and CD4+ and CD8+ T cell subsets, regardless of disease phase. The gene discussed is CD4; the disease is myeloid sarcoma.